EUVIMEDEUVIMED entdecken
Übersichtsarbeit

TRK inhibitors in cancer therapeutics: Recent advances and future perspectives

Hong-Ye Liu, Ying-Hao Sun, Yan-Ping Wang, Xu Zhang, Shuai Guo, Lin Wang, Fan-Hao Meng, Ting-Jian Zhang

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.109534 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Hong-Ye Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, Nor…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Neoplasms, Antineoplastic Agents, Receptor, trkA. Die Arbeit nennt 108 Literaturangaben. Gefördert von: Ministry of Education, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tropomyosin receptor kinase (TRK), belonging to the tyrosine kinase family, is associated with tumor proliferation, invasion, and survival in various cancers. Upon activation by neurotrophic factors, TRK regulates crucial cellular processes through downstream signaling pathways. Dysregulation of TRK signaling can lead to a range of diseases including cancers. Moreover, mutations in TRK kinases leading to resistance remain a critical issue, necessitating the discovery of new TRK inhibitors to overcome acquired resistance. Recently, several selective TRK inhibitors have been reported, making it possible to address off-target effects and adverse reactions associated with the target. This review summarizes the recent advances in small molecular TRK inhibitors with diverse structural types, activities, and selectivity. It highlights promising small molecules that have shown breakthrough achievements in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsNeoplasmsAntineoplastic AgentsReceptor, trkAReceptor Protein-Tyrosine KinasesHumansAnimalsMolecular StructureTyrosine Kinase InhibitorsCell Proliferation

Stichwörter der Autor:innen

Kinase inhibitorsNTRK fusionTropomyosin receptor tyrosine kinase

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsReceptor, trkATyrosine Kinase InhibitorsReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China.
  • School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China. Electronic address: wanglin@cmu.e…
  • School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China. Electronic address: fhmeng@cmu.ed…
  • School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China; Engineering Research Center of Tr…

Förderung

  • Ministry of Education
  • National Natural Science Foundation of China

Zitieren

APA

Liu, H. Y., Sun, Y. H., Wang, Y. P., Zhang, X., Guo, S., Wang, L., Meng, F. H., & Zhang, T. J. (2026). TRK inhibitors in cancer therapeutics: Recent advances and future perspectives. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109534

Vancouver

Liu HY, Sun YH, Wang YP, Zhang X, Guo S, Wang L, et al. TRK inhibitors in cancer therapeutics: Recent advances and future perspectives. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109534

BibTeX
@article{Liu2026,
  author = {Liu, Hong-Ye and Sun, Ying-Hao and Wang, Yan-Ping and Zhang, Xu and Guo, Shuai and Wang, Lin and Meng, Fan-Hao and Zhang, Ting-Jian},
  title = {TRK inhibitors in cancer therapeutics: Recent advances and future perspectives},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.109534}
}
Kostenlos starten →